Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Inc (CGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 125,349
  • Shares Outstanding, K 88,274
  • Annual Sales, $ 0 K
  • Annual Income, $ -33,970 K
  • EBIT $ -45 M
  • EBITDA $ -45 M
  • 60-Month Beta 1.26
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 3
  • High Estimate -0.05
  • Low Estimate -0.07
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +64.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.3300 +10.53%
on 12/31/25
1.6100 -8.70%
on 12/23/25
-0.1200 (-7.55%)
since 12/22/25
3-Month
1.3014 +12.96%
on 11/21/25
1.8300 -19.67%
on 10/31/25
-0.2300 (-13.53%)
since 10/22/25
52-Week
0.2223 +561.27%
on 05/28/25
3.8300 -61.62%
on 08/25/25
+0.7007 (+91.08%)
since 01/22/25

Most Recent Stories

More News
Cognition Therapeutics Publishes Phase 2 Clinical Results Showing Zervimesine’s Potential to Slow the Progression of Dementia with Lewy Bodies

PURCHASE, N.Y., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), today announced that a manuscript entitled, “Phase 2 Study of Zervimesine (CT1812) in Participants with Mild-to-Moderate...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Presents Phase 3 Plan for Zervimesine (CT1812) in Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

- Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting - - Actively Evaluating Strategy Across DLB and Alzheimer’s Disease - PURCHASE, N.Y., Dec. 01, 2025 (GLOBE NEWSWIRE)...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics to Participate in 37th Annual Piper Sandler Healthcare Conference

PURCHASE, N.Y., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates designed to treat neurodegenerative disorders, announced...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Completes Enrollment in Phase 2 Study of Zervimesine (CT1812) in Early Alzheimer’s Disease

PURCHASE, N.Y., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders,...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Reports Financial Results for the Third Quarter 2025 and Highlights Progress Across Clinical Programs

- $30 Million Registered Direct Offering Support Next Stage of Development for Zervimesine (CT1812) - - Aligned with U.S. FDA on Registrational Path for Zervimesine - - Expanded Access Program...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders,...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock

- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative...

CGTX : 1.4750 (+3.87%)
Cognition Therapeutics Receives End-of-Phase 2 Meeting Minutes Confirming Alignment with U.S. FDA on Registrational Path for Zervimesine (CT1812) in Alzheimer’s Disease

- Cognition and FDA align on enriched population, study design, and endpoints - PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ:...

CGTX : 1.4750 (+3.87%)

Business Summary

Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE,...

See More

Key Turning Points

3rd Resistance Point 1.4933
2nd Resistance Point 1.4667
1st Resistance Point 1.4433
Last Price 1.4750
1st Support Level 1.3933
2nd Support Level 1.3667
3rd Support Level 1.3433

See More

52-Week High 3.8300
Fibonacci 61.8% 2.4519
Fibonacci 50% 2.0261
Fibonacci 38.2% 1.6004
Last Price 1.4750
52-Week Low 0.2223

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar